Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Narya Capital

Investor type Venture Capital
Founders Colin Greenspon J.D. Vance

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 12
Average round size
info
The average size of a deal this fund participated in
$66M
Portfolio companies 8
Rounds per year 4.00
Lead investments 1
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.33
Exits 1
Key employees Soon

Areas of investment

  • Life Science
  • Biotechnology
  • Information Technology
  • AgTech
  • Agriculture

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Narya Capital:
Typical Co-investors
Narya Capital is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Narya Capital:
There are no funds here. If we find new data, we will add it here.

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Boston Life Science Venture Taipei, Taiwan
Cathay Venture Taipei, Taiwan
Eventide Risk Management -
Gary Community Investments Colorado, Denver, United States
Good Technology California, Sunnyvale, United States
Huawei Technologies China, Guangdong, Shenzhen
INROADS Capital Partners Evanston, Illinois, United States
McDonald Partners Cleveland, Ohio, United States
PlayFast Games -
Rhon-Klinikum Bad Neustadt An Der Saale, Bavaria, Germany
Rungkai Capital Beijing, Changyang, China
Startup Sauna Espoo, Finland, Uusimaa
Sunfire Entrepreneurs Club -
The Progressive Corporation Bay Village, Ohio, United States
Think.Health Bavaria, Bayern, Germany
Topfonds Gelderland -
WSR Capital Colorado, Highlands Ranch, United States
Youshan Capital Beijing, Beijing, China
Zencoder California, San Francisco, United States

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Branch Insurance

Auto Insurance
Insurance
InsurTech
Property Insurance
$147M08 Jun 2022 Columbus, Ohio, United States

Kriya Therapeutics

Biotechnology
Life Science
$270M16 May 2022 Palo Alto, California, United States

Strive Asset Management

Financial Services
$20M09 May 2022 Columbus, Ohio, United States

AcreTrader

Agriculture
AgTech
Asset Management
FinTech
Real Estate Investment
$40M11 Jan 2022 Fayetteville, Arkansas, United States

Hallow

Information Technology
Internet
$40M03 Nov 2021 Chicago, Illinois, United States

Chapter

Consumer Reviews
Health Care
Health Insurance
Information Technology
Medical
$17M21 Sep 2021 New York, New York, United States

Kriya Therapeutics

Biotechnology
Life Science
$100M14 Jul 2021 Palo Alto, California, United States

Rumble.com

Content Creators
Content Delivery Network
Content Discovery
Content Syndication
Video
Video Streaming
20 May 2021 Old Toronto, Ontario, Canada

AcreTrader

Agriculture
AgTech
Asset Management
FinTech
Real Estate Investment
$12M11 Mar 2021 Fayetteville, Arkansas, United States
News
Chapter Raises $17M in Series A Funding

– Chapter is a New York-based Medicare Advisor.
– The company raised $17M in Series A funding.
– The round was led by Narya Capital with participation from Susa Ventures, Maverick Ventures, XYZ Venture Capital, Core Innovation Capital and Health2047 Capital Partners.
– The new investment will be used to accelerate the company’s product development efforts, expand its team of engineers and licensed advisors, and further invest in supporting its members.

Kriya Therapeutics Completes $100 Million Series B Financing to Advance Its Fully Integrated Platform for Designing, Developing and Manufacturing Transformative Gene Therapies

– Kriya closed a $100m Series B financing to support its mission of transforming the design, development and manufacturing of gene therapies.
– The financing was led by Patient Square Capital with participation from new investors Woodline Partners LP, CAM Capital, Hongkou, Alumni Ventures and others.
– All existing institutional investors also participated in this round, including QVT, Dexcel Pharma, Foresite Capital, Bluebird Ventures, Transhuman Capital, Narya Capital, Amplo and JDRF T1D Fund.
– Proceeds from the financing will be used to further develop Kriya’s core technology platforms, expand its therapeutic pipeline and advance its current programs in metabolic disease, ophthalmology and oncology.
– Jim Momtazee, Managing Partner of Patient Square Capital, will join Kriya’s Board of Directors.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Narya Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: